Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Skovsgaard

Showing results (31-40 of 72) with videos related to

Pageof 8
Sort By:
Virchows Archiv. B, Cell Pathology Including Molecular Pathology|January 1, 1989
Freeze-fracture study of plasma membranes in wild type and daunorubicin-resistant Ehrlich ascites tumor and P388 leukemia cellsM Sehested, D Simpson, T Skovsgaard, et al.
Biochimica Et Biophysica Acta|August 22, 1997
Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activityT Litman, T Zeuthen, T Skovsgaard, et al.
Biochimica Et Biophysica Acta|August 22, 1997
Structure-activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activityT Litman, T Zeuthen, T Skovsgaard, et al.
European Journal of Cell Biology|December 1, 1988
Proopiomelanocortin producing cells of spleen: increase after transplantation with opioid-peptide producing Ehrlich ascites tumor cellsL I Larsson, P Blume-Jensen, T Skovsgaard, et al.
Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. Section A, Pathology|November 1, 1987
Interaction among two subpopulations of Ehrlich ascites tumor in vivo: evidence of a contact mediated immune responseK Aabo, L L Vindeløv, T Skovsgaard, et al.
Clinical Chemistry|October 1, 1993
Interpretation of results for tumor markers on the basis of analytical imprecision and biological variationG Sölétormos, V Schiøler, D Nielsen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2001
Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapyM Ryberg, D Nielsen, K Osterlind, et al.
Clinical Chemistry|April 1, 1996
Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-upG Sölétormos, D Nielsen, V Schiøler, et al.
Acta Oncologica (Stockholm, Sweden)|November 27, 1998
Challenging drug resistance in cancer therapy--review of the First Nordic Conference on Chemoresistance in Cancer Treatment, October 9th and 10th, 1997G Lehne, E Elonen, M Baekelandt, et al.
Journal of the National Cancer Institute|January 1, 1987
Increase in nonspecific adsorptive endocytosis in anthracycline- and vinca alkaloid-resistant Ehrlich ascites tumor cell linesM Sehested, T Skovsgaard, B van Deurs, et al.
Pageof 8

Showing results (31-40 of 72) with videos related to

Sort By:
Pageof 8
Virchows Archiv. B, Cell Pathology Including Molecular Pathology|January 1, 1989
Freeze-fracture study of plasma membranes in wild type and daunorubicin-resistant Ehrlich ascites tumor and P388 leukemia cellsM Sehested, D Simpson, T Skovsgaard, et al.
Biochimica Et Biophysica Acta|August 22, 1997
Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activityT Litman, T Zeuthen, T Skovsgaard, et al.
Biochimica Et Biophysica Acta|August 22, 1997
Structure-activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activityT Litman, T Zeuthen, T Skovsgaard, et al.
European Journal of Cell Biology|December 1, 1988
Proopiomelanocortin producing cells of spleen: increase after transplantation with opioid-peptide producing Ehrlich ascites tumor cellsL I Larsson, P Blume-Jensen, T Skovsgaard, et al.
Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. Section A, Pathology|November 1, 1987
Interaction among two subpopulations of Ehrlich ascites tumor in vivo: evidence of a contact mediated immune responseK Aabo, L L Vindeløv, T Skovsgaard, et al.
Clinical Chemistry|October 1, 1993
Interpretation of results for tumor markers on the basis of analytical imprecision and biological variationG Sölétormos, V Schiøler, D Nielsen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2001
Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapyM Ryberg, D Nielsen, K Osterlind, et al.
Clinical Chemistry|April 1, 1996
Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-upG Sölétormos, D Nielsen, V Schiøler, et al.
Acta Oncologica (Stockholm, Sweden)|November 27, 1998
Challenging drug resistance in cancer therapy--review of the First Nordic Conference on Chemoresistance in Cancer Treatment, October 9th and 10th, 1997G Lehne, E Elonen, M Baekelandt, et al.
Journal of the National Cancer Institute|January 1, 1987
Increase in nonspecific adsorptive endocytosis in anthracycline- and vinca alkaloid-resistant Ehrlich ascites tumor cell linesM Sehested, T Skovsgaard, B van Deurs, et al.
Pageof 8